01 — At a Glance
The Generics Darling That Became a CDMO Laboratory
- 52-Week High / Low₹1,141 / ₹517
- Q3 FY26 Revenue₹1,778 Cr
- Q3 FY26 PAT₹252 Cr
- Q3 EPS₹4.66
- Annualised EPS (Q3×4)₹18.64
- Book Value₹89.0
- Price to Book11.5x
- OPM (Q3)27.0%
- Debt to Equity0.46x
- 9M FY26 PAT₹610 Cr
Opening Thought: Laurus delivered ₹1,778 crore revenue in Q3 FY26 (+26% YoY), with PAT of ₹252 crore. Generics segment exploded 37% YoY to ₹1,327 crore. CDMO grew >50% YoY on a 9M basis. Operating margin was 27%. And yet, P/E is 65.7x while ROCE lingers at 18.5%. For context, Cipla trades at 22.4x with 22.7% ROCE. This is not a normal pharma valuation. This is a biotech startup wearing a generics suit.
02 — Introduction
Welcome to the Pharmaceutical Multiverse
Laurus Labs was founded in 2005 and spent its first 15 years being a boring, competent API (Active Pharmaceutical Ingredient) and generic formulations company. It made antiretroviral drugs for HIV patients, steroids, and cardiovascular APIs. Boring, steady, profitable. Then around FY22, management decided being profitable was insufficient. They wanted to be transcendent.
Enter: the CDMO (Contract Development and Manufacturing Organisation) pivot. Enter: the biotech dreams. Enter: peptides, ADCs (Antibody-Drug Conjugates), gene therapies, and immersion cooling fluids for data centres. Suddenly, a ₹5,500 crore ARV and generic API company started investing ₹1,000+ crore annually in capex to build facilities for molecules that don’t exist yet.
The stock went from ₹100 in March 2023 to ₹1,026 today — a 10x run in three years. But here’s where it gets spicy: the company is now being valued like a biotech unicorn despite still earning 85% of its revenues from unexciting generics and APIs. And despite burning capex like a startup, management keeps insisting they’re “progressing well.” Welcome to the Laurus Labs masterclass in investor expectations management.
Reality Check: In the Jan 2026 concall, when asked if the new modalities (ADCs, GT) would contribute meaningfully in next 24 months, the CEO flatly said: “We don’t expect any meaningful revenues coming from ADCs… for the next two years.” Translation: you’re paying 65x earnings for hope, not earnings.
03 — Business Model: Portfolio Chaos (Politely)
APIs, Generics, CDMO, Biotech — Pick a Lane and Stay There
Laurus operates across four distinct business units, each with its own gravitational pull:
Generic APIs (46% Revenue in 9M FY25)
Antiretrovirals (ARV), oncology, steroids, cardiovascular — selling bulk chemicals to generic pharma companies worldwide. Think Aurobindo, Cipla, Mankind. The profit margin here is stable but pricing pressure is eternal. ARV specifically: 59% of API revenue. Management guided ARV at ~₹2,600 crore ±200 crore on an annual run-rate. It’s not growing. It’s stabilising. It’s the cash cow that funds everything else.
Generic Formulations (27% Revenue in 9M FY25)
Finished oral solid drugs for ARVs, diabetes, cardiovascular therapies — selling pills to patients in developing markets. Margins are lower than APIs. Competition is brutal. But management is scaling this. In Q3, generics revenue hit ₹1,327 crore (+37% YoY). New capacity coming online. Oral solid expansion “significant part operational in Q3.”
CDMO Synthesis (24% Revenue in 9M FY25)
Custom synthesis division (Laurus Synthesis) does contract manufacturing for global biotech and pharma innovators. Think small-molecule drug development for US/EU biotech companies. Q3 small-molecule CDMO was ₹408 crore. 9M CDMO grew >50% YoY. Management has 70+ active projects, 10 commercial. This is high-margin, lumpy, and addictive for growth narratives.
Biotechnology (3% Revenue in 9M FY25)
Subsidiary Laurus Bio does microbial fermentation for nutraceuticals, cosmeceuticals, cultured meat. Raised ₹120 crore from global VCs (Eight Roads Ventures, F-Prime Capital) in December 2024. Building a 400 KL fermentation facility in Vizag by end of 2026. Currently muted. Upside optionality.
The Complication: Management is also building peptide manufacturing, ADC GMP facilities (₹25 crore allocated), and gene therapy capabilities, but revenues from these won’t show up for 24+ months. You’re funding the dream today. Profitability comes later. Or never. Biotechs are lottery tickets dressed as pharmaceutical companies.
04 — Financials: The Good, The Lumpy, The Expensive
Q3 FY26: Numbers That Look Good If You Squint
Result type: Quarterly Results | Q3 FY26 EPS: ₹4.66 | Annualised EPS (Q3×4): ₹18.64 | 9M FY26 EPS: Approx ₹11.34 (₹610 Cr / 53.8 Cr shares)
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 1,778 | 1,415 | 1,653 | +25.7% | +7.6% |
| Operating Profit | 480 | 285 | 403 | +68.4% | +19.1% |
| OPM % | 27.0% | 20.1% | 24.4% | +690 bps | +260 bps |
| PAT | 252 | 93 | 194 | +172.0% | +30.0% |
| EPS (₹) | 4.66 | 1.71 | 3.61 | +172.5% | +29.1% |
Behind the Scenes: Q3 PAT of ₹252 crore looks phenomenal YoY (+172%), but here’s the thing: Q3 FY25 had a tax anomaly. Effective tax rate was 31% in Q3 FY25 vs 22% in Q3 FY26. This inflated the YoY comparison. More telling: 9M FY26 PAT is ₹610 crore (+388% YoY). That growth is obscene. Why? Because 9M FY25 was plagued by facility ramp-ups, capex depreciation, and pre-operative expenses. The base was tiny. Now that stuff is amortising. Apples and oranges.
9M FY26 Revenue₹5,001 Cr+30% YoY
Gross Margin60%Guided to maintain
EBITDA Margin26.1%9M FY26 average
Management Guidance (Jan 2026 Concall): “Expect to maintain gross margins of around 60% for the coming quarter and also next financial year.” That’s credible. Cost inflation is being offset by better product mix (higher-margin CDMO), operational leverage, and productivity gains. But gross margin is different from operating margin. Depreciation from capex will compress OPM.
05 — Valuation: The Biotech Tax
65.7x P/E Is Not a Typo
Join 10,000+ investors who read this every week.
